Browse: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 3 |
Astrazeneca R&d Boston patentsThe following is a sampling of recent Astrazeneca R&d Boston patent applications (USPTO Patent Application #, Patent Title) sorted by month.
July 2009 - Astrazeneca R&d Boston patents
20090170849 - Quinazolinone derivatives having b-raf inhibitory activity
June 2009 - Astrazeneca R&d Boston patents
20090163524 - Novel protein kinase b inhibitors - 060
20090163524 - Novel protein kinase b inhibitors - 060
20090163525 - Substituted quinazolines with anti-cancer activity
20090163525 - Substituted quinazolines with anti-cancer activity
20090149484 - Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them
May 2009 - Astrazeneca R&d Boston patents
20090137601 - L-phenylalanine derivatives
20090137624 - Chemical compounds
20090131444 - Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
20090131463 - Novel compounds
20090123474 - Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
20090123476 - Targeted binding agents directed to upar and uses thereof
20090123478 - Human antibody molecules for il-13
20090118220 - Substituted adenines and the uses thereof
20090118261 - Quinazolinone derivatives and their use as b-raf inhibitors
20090118305 - Pyridine and pyrazine derivatives - 083
April 2009 - Astrazeneca R&d Boston patents
20090111828 - L-alanine derivatives
20090111860 - Sulfonamide compounds useful as adg receptor modulators
20090105324 - Imidazole derivatives for use as edg-1 antagonists
20090105324 - Imidazole derivatives for use as edg-1 antagonists
20090105324 - Imidazole derivatives for use as edg-1 antagonists
20090099174 - Combination 059
20090099203 - Composition 064
20090099210 - Enantiomers of selected fused heterocyclics and uses thereof
March 2009 - Astrazeneca R&d Boston patents
20090060919 - Binding members for ige molecules
20090062246 - Therapeutic treatment-014
20090062267 - L-alanine derivatives as a5beta1 antagonists
February 2009 - Astrazeneca R&d Boston patents
20090054394 - Polymorphisms in mgst3 are associated with elevated alat levels after ximelagatran treatment
20090054396 - Substituted thiophenes and uses thereof
20090054398 - Chemical compounds
20090054411 - 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors
20090054428 - Novel pyrimidine derivatives 965
20090054469 - Quinazolinone derivatives and their use as b-raf inhibitors
20090048203 - Substituted adenines and the uses thereof
20090048269 - Chemical compounds-821
20090036424 - Association between hla-drbi*07 allele and susceptibily to increased levels of alat following ximelagatran administration
January 2009 - Astrazeneca R&d Boston patents
20090029367 - Polymorphisms in pon1 are associated with elevated alanine aminotransferase levels after ximelagatran or tacrine administration
20090029991 - Benzamide derivatives useful as histone deacetylase inhibitors
20090023719 - Pyrimidine derivatives 934
20090012084 - 3-cinnolinecarboxamide derivatives and their use for treating cancer
October 2008 - Astrazeneca R&d Boston patents
20080261240 - Method
20080262811 - Crystal structure of haemophilus influenzae nad dependent dna ligase and uses thereof
20080255105 - Biphenyl derivatives and their use in treating hepatitis c
20080255183 - N-[heteroarylcarbonyl]-3-thienyl-l-alanine derivatives as a5beta1 antagonists
20080248048 - Interleukin-13 antibody composition
20080248077 - Formulation
20080242663 - Novel pyrimidine derivatives 698
September 2008 - Astrazeneca R&d Boston patents
20080221124 - Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4-[1, 3, 4-oxadiazole-2-yl] phenyl) pyridine-3-sulphonamide
August 2008 - Astrazeneca R&d Boston patents
20080206303 - Prolonged release formulations comprising anastrozole
20080207616 - Quinoxalines as b baf inhhibitors
20080199481 - Compounds
20080200649 - Method
20080194552 - Aminopyrimidine derivatives with tie2 inhibiting activity
20080194556 - Quinazolines and their use as aurora kinase inhibitors
20080194606 - Pyrazolyl-amino-substituted pyrimidines and their use in the treatment of cancer
July 2008 - Astrazeneca R&d Boston patents
20080182842 - L-alanine derivatives as a5beta1 antagonists
20080175834 - Carboxypertidase u (cpu) mutants
20080176872 - Chemical compounds
20080171742 - 4-(pyrid-2-yl) amino substituted pyrimidine as protein kinase inhibitors
20080167297 - Pyrimidine derivatives for use as anticancer agents
20080161278 - 2-azetidinyl-4-(1h-pyrazol-3-ylamino) pyrimidines as inhibitors of insulin-like growth factor-1 receptor activity
20080161306 - Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
20080161330 - Pyrimidines as igf-i inhibitors
20080161404 - Bicalutamide for delivering increasing steady state plasma levels
20080161565 - Chemical process
June 2008 - Astrazeneca R&d Boston patents
20080153799 - Novel quinoline-carbaxamides as jak3 kinase modulators
20080153812 - Novel compounds
20080153838 - Compounds having tie2 (tek) activity
20080153854 - Novel fused heterocycles and uses thereof
20080145358 - Method for determining responsiveness to chk1 inhibitors
20080145840 - Isothermal titration calorimetry assays
20080146570 - Chemical compounds
20080146599 - Pyrimidine compounds having tie-2 (tek) inhibitory activity
20080139561 - Pyrazolylaminopyridine derivatives useful as kinases inhibitors
20080132546 - Chemical compounds
May 2008 - Astrazeneca R&d Boston patents
20080119451 - Novel benzamide derivatives
20080108608 - Pyrimidines with tie2 (tek) activity
March 2008 - Astrazeneca R&d Boston patents
20080076780 - Combination of n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent
20080064691 - Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity
February 2008 - Astrazeneca R&d Boston patents
20080045481 - Novel co-crystal
20080045517 - 6h-thieno[2,3-b]pyrrole derivatives as antagonists of gonadotropin releasing hormone (gnrh)
20080045521 - Phenylalanine derivatives
January 2008 - Astrazeneca R&d Boston patents
20080027076 - Pyrimidines with tie2 (tek) activity
20080020416 - Enzyme and preparation method
20080021012 - 3-[4-{6-substituted alkanoyl pyridin-3-yl}-3-phenyl]-5-(1h-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents
20080009482 - Novel compounds
20080009512 - Tetrahydroquinolones and aza-analogues thereof for use as dpp-iv inhibitors in the treatment of diabetes
20080004302 - Novel compounds
December 2007 - Astrazeneca R&d Boston patents
20070298413 - Topoisomerase modulators assays
20070287703 - Fused pyrimidones useful in the treatment and the prevention of cancer
20070281916 - Substituted isoxazolines and their use as antibacterial agents
November 2007 - Astrazeneca R&d Boston patents
20070275954 - Novel fused heterocycles and uses thereof
20070275982 - Method
20070270384 - Process and intermediate
20070259849 - Azine-carboxamides as anti-cancer agents
October 2007 - Astrazeneca R&d Boston patents
20070249636 - Selected fused heterocyclics and uses thereof
August 2007 - Astrazeneca R&d Boston patents
20070202548 - Screening assay to identify inhibitors of the murd enzyme using an activator-independent murd enzyme
20070185106 - Pyrrole derivatives as gonadotropin releasing hormone (gnrh) antagonists
20070185185 - Derivatives of thienopyrrole as gnrh antagonists
July 2007 - Astrazeneca R&d Boston patents
20070172425 - Testing cell cycle regulation effect of a compound using a hollow fibre cell implant
20070167428 - Thienopyrroles as antagonists of gnrh
June 2007 - Astrazeneca R&d Boston patents
20070149560 - Novel fused triazolones and the uses thereof
20070142413 - Pyrazole derivatives as inhibitors of receptor tyrosone kinases
20070135455 - Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2
May 2007 - Astrazeneca R&d Boston patents
20070123528 - Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
20070117138 - Splice variant cannabinoid receptor (cb1b)
April 2007 - Astrazeneca R&d Boston patents
20070092879 - Fluoresence-based dna primase assays
February 2007 - Astrazeneca R&d Boston patents
20070043069 - Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase
20070037888 - 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
January 2007 - Astrazeneca R&d Boston patents
20070010556 - Thiophene derivatives as chk 1 inhibitors
December 2006 - Astrazeneca R&d Boston patents
20060287241 - Combination comprising n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazol-2-y1]pyridine-3-sulphonamide and an lhrh analogue and/or bisphosphonate
20060287379 - Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
20060281666 - Substitute thiophenes and uses therof
November 2006 - Astrazeneca R&d Boston patents
20060270637 - Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents
20060270689 - Novel fused heterocycles and uses thereof
20060270692 - Chemical compounds
20060263298 - Assay
20060264494 - Heterocyclic amide derivatives which process glycogen phorylase inhibitory activity
20060258710 - Indolylalkylamino-methylidenecarbamate derivatives useful as gnrh antagonists
20060252781 - Fused heterocycles as inhibitors of glutamate racemase(muri)
October 2006 - Astrazeneca R&d Boston patents
20060235067 - 6h-thieno[2,3-b]pyrrole derivatives as antagonists of gonadotropin releasing hormone (gnrh)
20060223801 - Pyrrol derivatives with antibacterial activity
September 2006 - Astrazeneca R&d Boston patents
20060216774 - Method
20060211760 - Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
20060199966 - Indol-2-amides as glycogen phosphorylase inhibitors
###
This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Astrazeneca R&d Boston in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Astrazeneca R&d Boston with additional patents listed. Browse our Agent directory for other possible listings.
###
FreshPatents.com Support
|
REGISTER now for FREE 
